http://www.bing.com:80/search?q=Recursion+ModelSearch resultshttp://www.bing.com:80/s/a/rsslogo.gifhttp://www.bing.com:80/search?q=Recursion+ModelCopyright © 2026 Microsoft. All rights reserved. These XML results may not be used, reproduced or transmitted in any manner or for any purpose other than rendering Bing results within an RSS aggregator for your personal, non-commercial use. Any other use of these results requires express written permission from Microsoft Corporation. By accessing this web page or using these results in any manner whatsoever, you agree to be bound by the foregoing restrictions.https://www.recursion.com/Our data and the Recursion OS enable us to train intelligent machine learning models for AI drug discovery and development, which help us rapidly identify new targets and design highly optimized molecules that fuel our pipeline of potential first-in-class and best-in-class medicines.Wed, 08 Apr 2026 21:23:00 GMThttps://www.recursion.com/missionRecursion's TechBio approach: The future of AI drug discovery In traditional drug discovery, 90% of drugs fail in clinical trials, after more than a decade in development and ~$2 billion in costs. We’re changing the paradigm – leading with data, AI, and an industrialized approach to dramatically improve the cost, timeline, and probability of success of developing new medicines — because ...Thu, 09 Apr 2026 09:26:00 GMThttps://www.recursion.com/pipelineExplore Recursion's dynamic drug discovery pipeline. Witness the innovations and breakthroughs in our journey. Dive deeper with us today!Mon, 06 Apr 2026 03:11:00 GMThttps://www.recursion.com/platformCentral to our mission is the Recursion Operating System (OS), a platform powered by one of the world’s largest proprietary biological and chemical datasets. Instead of looking narrowly at a handful of diseases with existing therapeutic hypotheses, we build Maps of Biology and Chemistry that broaden our search and allow us to explore unknown areas of disease biology.Wed, 08 Apr 2026 05:03:00 GMThttps://ir.recursion.com/news-releases/news-release-details/recursion-reports-fourth-quarter-and-full-year-2025-financialSALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and full year ending December 31, 2025.Sun, 05 Apr 2026 23:00:00 GMThttps://ir.recursion.com/Recursion Pharmaceuticals is a clinical stage TechBio company decoding biology to radically improve lives. Recursion is advancing a portfolio of differentiated investigational medicines across its wholly owned and partnered pipeline in oncology, rare disease, neuroscience, immunology, and other therapeutic areas with significant unmet need.Tue, 07 Apr 2026 13:25:00 GMThttps://www.recursion.com/careersEmbark on a career journey with Recursion. Dive into opportunities, culture, and the impact you can make. Apply to work with us today!Wed, 08 Apr 2026 05:03:00 GMThttps://ir.recursion.com/news-releases/news-release-details/positive-phase-1b2-results-ongoing-rec-4881-tupelo-trial-0ir.recursion.comWed, 08 Apr 2026 12:41:00 GMThttps://www.recursion.com/teamGet acquainted with the brilliant minds behind Recursion. Dive into our team's passion, expertise, and vision. Read more about our team today!Wed, 08 Apr 2026 01:42:00 GMThttps://www.recursion.com/news/how-a-first-of-its-kind-microglia-map-from-recursion-and-roche-and-genentech-could-unlock-new-treatments-for-neurodegenerative-diseasesA first-of-its-kind whole genome map from researchers at Recursion with partners Roche and Genentech offers a new approach to exploring novel targets and pathways for a wide range of neurological diseases.Wed, 08 Apr 2026 16:08:00 GMT